Related Experiment Video
Updated: Jul 28, 2025

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
High Rates of ESBL-producing and Gentamycin-resistant Gram-negative Bacteria During the First Week of Life: A
Muhammad Washahi1, Dan Miron2, Zohar Steinberg Ben Zeev2
1From the Pediatric Department.
Insights
In infants under two months with urinary tract infections (UTIs), Extended Spectrum Beta-Lactamase (ESBL) and gentamicin resistance are significant concerns. Higher resistance rates in the first week of life suggest a need for treatment protocol review.
Area of Science:
- Pediatrics
- Infectious Diseases
- Microbiology
Background:
- Urinary tract infections (UTIs) in infants require prompt antimicrobial treatment to prevent renal scarring.
- Current recommendations for febrile infants under 2 months involve empirical gentamicin and ampicillin.
- The rise of antimicrobial resistance necessitates evaluating the effectiveness of these treatments.
Purpose of the Study:
- To determine the prevalence of Extended Spectrum Beta-Lactamase (ESBL)-producing and gentamicin-resistant Gram-negative UTIs in infants younger than 2 months.
- To identify factors associated with these resistant bacterial infections in this age group.
Main Methods:
- A multicenter retrospective cross-sectional study was conducted.
- Data were collected from pediatric emergency departments between January 2016 and December 2021.
- The study included 1142 infants under 2 months with UTIs.
Main Results:
- The prevalence of gentamicin-resistant UTI was 5.7%, and ESBL-producing UTI was 5.6%.
- Infants in the first week of life exhibited higher rates of both ESBL (14.8%) and gentamicin resistance (11.2%).
- Higher admission rates to pediatric intensive care units (ICUs) were observed in infants with ESBL-associated UTIs (9.8%).
Conclusions:
- Current empirical treatment guidelines are generally supported.
- Treatment protocols may require modification for infants younger than 7 days due to elevated resistance rates.
- Further investigation into resistance patterns in neonates is warranted.
Introduction:
Reducing the risk of renal scarring in infants with urinary tract infection (UTI) necessitates timely and effective administration of antimicrobial treatment. The Israeli Medical Association recommends the empirical use of gentamicin and ampicillin for febrile infants younger than 2 months with suspected UTI. We aimed to assess the prevalence of Extended Spectrum Beta-Lactamase (ESBL)-producing and gentamicin-resistant Gram-negative UTI among infants younger than 2 months.
Methods:
A multicenter retrospective cross-sectional study of infants younger than 2 months with UTI who visited Clalit Health Services pediatric emergency departments between January 1, 2016, and December 31, 2021. The primary outcome measure was the prevalence of ESBL-associated and gentamicin-resistant UTI. The secondary outcome measure was the factors associated with such resistant bacteria.
Results:
Overall, 1142 infants were included. Sixty-five (5.7%) and 64 (5.6%) infants had gentamicin-resistant and ESBL-producing Gram-negative UTI, respectively. Forty-two percent of ESBL-associated UTI were gentamicin-resistant. Higher ESBL rates were found during first week of life (14.8% versus 4.1%-7.7%; P = 0.009). Similarly, higher rates of gentamicin resistance were found in this age group (11.2%). Admission rate to pediatric intensive care units (ICUs) was higher in infants with ESBL-associated UTI (9.8% versus 3.5%; P = 0.015). Gestational bacteriuria, previous neonatal ICU admission or gender were not associated with either gentamicin or ESBL-producing resistance.
Conclusions:
Our findings support the current recommendations for empirical intravenous treatment. However, modification of the treatment protocol should be considered for infants younger than 7 days, who had higher rates of ESBL-producing and gentamicin-resistant Gram-negative UTI.
Related Concept Videos
Urine Studies II: Urine Culture and Sensitivity Test
Acute Pyelonephritis II: Diagnostic Studies and Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Urinary Tract Infection I: Introduction

